SYK Stryker Corporation SURGICAL & MEDICAL INSTRUMENTS & APPARATUS Best Medical Devices Stocks 2026 →

Stryker (SYK) Stock: Buy, Sell, or Hold?

$309.64
-2.75 (-0.88%) â–ŧ
5d: -4.98% 30d: +5.6% 90d: -6.64%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (45%)
Quality Score
37/100
Position
FAIR
30-Day Fair Range
$284.79 – $319.60
Position: FAIR
Forward P/E & Valuation
19.0x FAIR
vs 20.1x historical avg
Wall Street Target
$339.37
+9.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$293.00 / $349.48
Trend: Downtrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
â„šī¸ NEUTRAL: SYK is fairly priced but lacks strong directional signals. At -1.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Tradestie Engineering & Supply-Chain Intelligence

SYK Technical Disclosures, Lab Velocity

5-Product Architecture Decomposition (MedTech, Surgical Robotics & Bionic Diagnostics): Mako SmartRobotics Total Knee, Hip, Spine & Shoulder Platform • 1788 4K Fluorescence & Endoscopic Surgical Visualization Tower • Triathlon Cementless 3D-Printed Tritanium Orthopedic Implants • Inari Medical ClotTriever / FlowTriever Mechanical Thrombectomy & Neurovascular • Vocera AI Clinical Workflow & LIFEPAK 35 Acute Care Connected Ecosystem
Inspect Product Architecture →

Get Alerted When SYK Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$456.62
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$283.53
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.1x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: SYK is currently trading at $309.64, which is considered fair relative to its 30-day fair value range of $284.79 to $319.60. The stock's valuation (Forward PE: 19.0) is in line with its historical norms (20.1). Remarkably, the market is currently pricing in an annual earnings decline of 1.8% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, SYK is in a downtrend. Immediate support is located at $293.00, while resistance sits at $349.48.

Market Sentiment: SYK scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position FAIR
Historical Trading Range $284.79 - $319.60
Company Quality Score 37/100 (SELL)
Volume Confirmation HIGH
Confidence Score 45.2%

Trading Range & Key Levels

30-Day Trading Range $284.79 - $319.60
Current vs Trading Range FAIR
Support Level $293.00
Resistance Level $349.48
Current Trend Downtrend
Technical data as of Nov 13, 2026

Protect Your Profits

Holding SYK? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Institutional Signals, 13F Whale Activity & Setup Structure

Quantitative Research Feed
Phase & Gamma Walls SURGE
Days in Phase: 7d (53% conf)
Put Wall / Support: $290 (1,845 OI)
Call Wall / Resist: $310 (3,280 OI)
Technical Setup Structure ACTIVE SETUP
Absorption: Inactive (CMF 0.24)
Pullback / Drawdown: -20.1% from 52W High
Consolidation: Active (ADX 18.0)
30D Insider Cluster Signal TRACKED
30D Insider Buyers: 0 insiders ($0)
30D Net Insider Flow: $-178,924,731

Quantitative Signal Breakdown

  • NEUTRAL: Price in fair range
  • BEARISH: Weak technical setup (15/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($339.37)
  • WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 19.01
Wall Street Target $339.37 (+9.6%)
Revenue Growth (YoY) 7.6%
Earnings Growth (YoY) -11.7%
Profit Margin 13.8%
Valuation Discount vs History -1.8% cheaper
PE vs Historical 19.0 vs 20.1 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -1.8% (market-implied from PE analysis)
1-Year Target $304.07 (-2%)
2-Year Target $298.59 (-4%)
3-Year Target $293.22 (-5%)
3-Yr Target (if PE normalizes) (PE: 19→20) $310.03 (+0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 19.9, Growth: 9.8%) $428.19 (+38%)
Base: (SPY PE: 19.0, Growth: 9.8%) $409.86 (+32%)
Bear: (PE: 16.2, Growth: 9.8%) $348.39 (+13%)
📈 Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33.3x PE), but valuation improves significantly next year (19.0x PE) as earnings recover.
Trailing PE: 33.27 | Current EPS (TTM): $9.39
Bull Case $596.07 (+93%)
Analyst growth 73.5%, PE expands to 36.6
Base Case $541.88 (+75%)
Market implied 73.5%, PE stable at 33.3
Bear Case $212.43 (-31%)
Severe decline -20.0%, PE contracts to 28.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.0 to 20.1
Stabilization Target: $327.39 (+5.7%)
PE Expansion Potential: +5.7%
Share SYK Analysis

Share this live SYK analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (SYK)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 30, 2026
Daily AI digest
AI Retail Discussion Summary: Stryker's ($SYK) stock fell 10% following a guidance cut and weak sales growth. The company's hip and knee market growth was below expectations, and CEO Kevin Lobo identified execution around the Mako robot as a bottleneck.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 16, 2026 1:47 AM ET
Data refreshes hourly during market hours. Next update: 2:47 AM
đŸ”Ĩ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for SYK.

Create Free Account

Already have an account? Log In

Top Rated Medical Devices Stocks

Top-rated stocks in Medical Devices by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
DXCM
DexCom Inc
STRONG BUY
29 analysts
$99 59 HOLD
BSX
Boston Scientific Corp
BUY
31 analysts
$50 48 HOLD
MDT
Medtronic PLC
BUY
30 analysts
$105 39 SELL
PODD
Insulet Corporation
BUY
26 analysts
$179 45 HOLD
IRTC
iRhythm Technologies Inc
STRONG BUY
16 analysts
$153 56 HOLD

Advanced SYK Option Strategies

Professional options setups generated by AI based on today's SYK price and gamma walls.

Iron Condor Bull Call Bear Put Collar

SYK Product Architecture & Supply Chain Bottlenecks

Open 5-Product Tear-Down Explorer →

Engineering decomposition of Stryker Corporation (SYK) across its 5 flagship products (MedTech, Surgical Robotics & Bionic Diagnostics), mapping critical upstream suppliers, sole-source choke points, and R&D velocity.

Mako SmartRobotics Total Knee, Hip, Spine & Shoulder Platform Sev 10/10
CT-based 3D preoperative planning + AccuStop haptic robotic arm boundary control expanding into spine and shoulder
Key Suppliers: ITGR TFX ATI RBC
1788 4K Fluorescence & Endoscopic Surgical Visualization Tower Sev 10/10
4K OLED/LED surgical camera system with SPY near-infrared fluorescence perfusion imaging
Key Suppliers: ITGR TFX ATI RBC
Triathlon Cementless 3D-Printed Tritanium Orthopedic Implants Sev 10/10
Additive-manufactured porous titanium implants engineered specifically for Mako robotic bone preparation
Key Suppliers: ITGR TFX ATI RBC
Inari Medical ClotTriever / FlowTriever Mechanical Thrombectomy & Neurovascular Sev 10/10
Catheter-based mechanical clot extraction for pulmonary embolism, DVT, and ischemic stroke
Key Suppliers: ITGR TFX MMSI ATI
Vocera AI Clinical Workflow & LIFEPAK 35 Acute Care Connected Ecosystem Sev 10/10
Smart hospital beds, connected defibrillators, and hands-free AI nursing communication
Key Suppliers: ITGR TFX ATI RBC
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals